Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals

AACR 2026 will showcase early clinical and preclinical updates across oncology modalities, including Merck’s first-in-human MK-2010 readout after its $588 million upfront license, Revolution Medicines’ zoldonrasib data, and D3 Bio’s elisrasib update. The meeting also features multiple ADC, DAC and protein degrader presentations, including GSK’s $185 million-upfront B7-H3 ADC and Roche’s up to $1 billion DAC deal with C4 Therapeutics. The news is broadly constructive for oncology innovation, but the impact is mainly event-driven and centered on trial readouts rather than confirmed commercial results.

Analysis

This meeting is less about headline data and more about whether the market starts assigning real option value to the “next backbone” oncology stack. The immediate winners are not the incumbents with today’s sales, but the platform names that can show credible differentiation in response durability, safety, or convenience; that is where re-rating can happen fastest in a space where each incremental data drop can reset partnering leverage. The second-order effect is a likely widening of the valuation gap between asset-rich innovators with near-term readouts and diversified pharmas that need the data to validate a strategy rather than a product.

The biggest setup risk is asymmetry around binary interpretation. For Merck and Summit, a merely “competitive” profile may be insufficient if the field is converging toward a new standard with better tolerability or broader utility; in that case, anything short of clear separation could be sold as a strategic setback despite still being investable long term. For KRAS, the market may be overestimating how quickly multiple programs translate into broad commercial franchises—coverage, sequencing, and biomarker narrowing can cap peak sales even if early response rates look strong.

The ADC and degrader themes are earlier and more levered to platform read-through than product revenue, which means the trade is mostly sentiment-driven over days to weeks. If the conference validates cancer-selective payloads or non-cereblon degrader approaches, the knock-on effect could be a higher probability of follow-on capital for specialist developers and a lower cost of capital for platform M&A targets. Conversely, disappointing toxicity or modest durability would quickly compress multiples because the market has already been rewarding modality expansion narratives more than hard cash flow.

Key Decisions for Investors

• Long RVMDW into the conference window, with a tight post-readout stop: best risk/reward if the zoldonrasib update confirms the earlier activity signal and extends durability; downside is large if the data look incremental, so size it as a 1-2 week event trade rather than a core position.
• Short SMMT vs long PFE as a pair trade over the next 2-6 weeks: if the Merck bispecific data show only parity rather than clear superiority, Summit’s narrative multiple is the more vulnerable leg while Pfizer retains broader pipeline optionality.
• Add a tactical long in GSK for 1-3 months if the ADC plenary shows manageable tolerability and competitive target engagement: the market is likely underpricing how quickly a credible B7-H3 readout can support partnering value; use a defined downside via call spreads.
• Selective long AMGN on any pullback tied to helicase-inhibitor skepticism: if the class continues to validate, it supports a higher-quality innovation premium for a name with balance-sheet capacity to monetize adjacent oncology shots on goal.
• Avoid chasing CCCC purely on platform enthusiasm; instead, wait for post-event confirmation. The upside is meaningful if DAC data broaden the field, but the first drawdown on mediocre data could be sharp because the valuation is currently more concept than earnings.